electroCore Inc
Company Profile
Business description
electroCore Inc is a commercial stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology. The company's product gammaCore is Food and Drug Administration cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients, and the prevention of migraine in adult patients, The use of gammaCore by adolescent patients and Treatment of hemicrania continua and paroxysmal hemicrania in adult patients.
Contact
200 Forge Way
Suite 205
RockawayNJ07866
USAT: +1 973 290-0097
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 December 2025
Employees
62
Stocks News & Analysis
stocks
Ask the analyst: Are IDP Education's woes temporary?
stocks
Is it time to buy the Magnificent Seven?
stocks
Chart of the week: Did ASX companies underwhelm or impress during earnings season?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 7,966.60 | 36.00 | -0.45% |
| CAC 40 | 7,938.21 | 50.75 | -0.64% |
| DAX 40 | 22,567.14 | 109.27 | -0.48% |
| Dow JONES (US) | 40,813.57 | 537.36 | -1.30% |
| FTSE 100 | 8,536.70 | 4.27 | -0.05% |
| HKSE | 23,462.65 | 137.66 | -0.58% |
| NASDAQ | 17,303.01 | 345.44 | -1.96% |
| Nikkei 225 | 36,790.03 | 29.06 | -0.08% |
| NZX 50 Index | 12,209.05 | 40.50 | -0.33% |
| S&P 500 | 5,521.52 | 77.78 | -1.39% |
| S&P/ASX 200 | 7,749.10 | 37.10 | -0.48% |
| SSE Composite Index | 3,358.73 | 13.20 | -0.39% |